← Browse by Condition
Medical Condition

psma positive metastatic castration resistant prostate cancer mcrpc with prior exposure to one prior arpi who are candidates for taxane based chemotherapy

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 1, Phase 2
NCT07226986 Phase 1, Phase 2
Recruiting

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

Enrollment
123 pts
Location
United States, Austr...
Sponsor
Novartis Pharmaceuticals
View Trial →